Photo of Steffen Koschmieder from ukaachen.de
Jun 18, 2024, 23:12
Koschmieder: Current standard and novel targets for myelofibrosis
Talha Badar shared on X: .
“Koschmieder: current standard and novel targets for myelofibrosis in 2024!
Koschmieder: novel combination trials
Koschmieder: current standard and novel targets for myelofibrosis in 2024!”
Source: Talha Badar/X
Dr. Talha Badar, MD, is a specialist in Hematology Oncology based in Mayo Clinic, Jacksonville, Florida. His primary areas of expertise include Leukemia, particularly Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Acute Lymphoblastic Leukemia (ALL), and Bone Marrow Transplantation. Over his career, he has actively contributed to clinical research and clinical trials.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 3, 2025, 22:35
Sep 3, 2025, 22:09
Sep 3, 2025, 20:48
Sep 3, 2025, 20:35
Sep 3, 2025, 20:10
Sep 3, 2025, 19:42
Sep 3, 2025, 18:59